Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IFC invests $15million in India's Hikal

This article was originally published in Scrip

Executive Summary

The International Finance Corporation (IFC), a member of the World Bank group, is investing $15 million in India'sHikal by way of equity participation. Hikal plans to issue up to 1.36 million equity shares of Rs10 each on a preferential basis to IFC, the company informed the Bombay Stock Exchange. The investment will part-finance Hikal's expansion plans at its existing sites in Jigani (near Bangalore), Panoli (Gujarat) and Taloja (near Mumbai). IFC believes that by supporting Hikal, a mid-tier player in contract research and manufacturing services, it will assist in the evolution and development of an emerging industry with long-term growth prospects and strong employment potential in India. Besides by supporting process innovation in emerging markets, IFC expects Hikal to further transform itself from competing on cost to competing on process capabilities.,

You may also be interested in...



The Golden Winged Warbler And Creating Pharma Supply Chain Immunity

Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.

Muted Q2 But Biocon Confident Of Insulin Glargine’s Onward US March

Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.

Muted Q2 But Biocon Confident Of Insulin Glargine’s Onward US March

Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.

Topics

UsernamePublicRestriction

Register

OM000882

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel